シスプラチン誘発性神経毒性に対する集団薬物遺伝学の影響
Swetha Nakshatri1, Paul C Dinh2, Lawrence H Einhorn2
1Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Cancer medicine
|September 6, 2025
まとめ
アフリカの祖先はシスプラチン誘発性神経病と頭の割合が高いと関連しています. RNF24,MFSD4B,およびREV3L遺伝子発現を含む遺伝的要因は,これらの化学療法副作用の違いを説明する可能性があります.
科学分野:
- ファルマゲノミクス
- 神経科学
- 腫瘍学
背景:
- シスプラチンは重要な化学療法剤で 周回神経症や頭などの神経毒性副作用が知られている.
- これらの毒性に対する 遺伝的影響を理解することは パーソナライズされたがん治療に不可欠です
研究 の 目的:
- シスプラチン誘発性神経毒性に対する遺伝的祖先の影響を調査する.
- 集団特有のアレル頻度が,化学療法による副作用の見られる差異に寄与するかどうかを調べる.
主な方法:
- シスプラチン治療を受けた丸癌の生存者からのデータを分析するために,ロジスティック回帰とクルスカル・ワリス試験が使用されました.
- シングルヌクレオチドポリモルフィズム (SNP) ゲノタイプは,集団のアレル頻度の違いを考慮して,神経毒性との関連を評価した.
主要な成果:
- アフリカ系の子孫の生存者は,ヨーロッパ系とアジア系の子孫の生存者と比較して神経病と頭の発生率が著しく高かった.
- 特定のSNP (例えば,rs34904346,rs3777909) と神経病/頭,RNF24,MFSD4B,およびREV3L遺伝子を含んだ示唆的な関連性が見つかりました.
結論:
- 遺伝的祖先はシスプラチン誘発性神経毒性において役割を果たし,アフリカ系祖先はリスクの増加と関連しています.
- RNF24,MFSD4B,およびREV3Lの遺伝子発現レベルは,これらの祖先に関連する格差の重要な要因である可能性があります.
関連する概念動画
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:12Analysis of Population Pharmacokinetic Data
381
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
381
01:21Factors Affecting Drug Response: Overview
2.3K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.3K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
293
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
293